REFERENCES
- Yavarian M, Karimi M, Bakker E, . Response to hydroxyurea treatment in Iranian transfusion-dependent β-thalassemia patients. Haematologica. 2004;89:1172–1178.
- Kumar B, Saraswat A, Kaur I. Rediscovering hydroxyurea: its role in recalcitrant psoriasis. Int J Dermatol. 2001;40:530–534.
- Biron F, Ponceeau B, Bouhour D, . Long-term safety and antiretroviral activity of hydroxyurea and didanosine in HIV-infected patients. J Acquir Immune Defic Syndr. 2000;25:329–336.
- Karimi M, Borzouee M, Mehrabani A, Cohan N. Echocardiographic finding in beta-thalassemia intermedia and major: absence of pulmonary hypertension following hydroxyurea treatment in beta-thalassemia intermedia. Eur J Haematol. 2009;82:213–218.
- Borgna-Pignatti C. Modern treatment of thalassaemia intermedia. Br J Haematol. 2007;138:291–304.
- Loukopoulos D, Voskaridou E, Stamoulakatou A, . Hydroxyurea therapy in thalassemia. Ann N Y Acad Sci. 1998;850:120–128.
- Hajjar FM, Pearson H. Pharmacologic treatment of thalassemia intermedia with hydroxyurea. J Pediatr. 1994;125:490–492.
- Zeng YT, Huang SZ, Ren ZR, . Hydroxyurea therapy in β-thalassemia intermedia: improvement in hematological parameters due to enhanced β-globin synthesis. Br J Hematol. 1995;90:557–563.
- Karimi M, Darzi H, Yavarian M. Hematological and clinical responses of thalassemia intermedia patients to hydroxyurea during 6 years of therapy in Iran. J Pediatr Hematol Oncol. 2005;27:380–385.
- Arruda VR, Lima CS, Saad ST, Costa FF. Successful use of hydroxyurea in beta-thalassemia major. N Engl J Med. 1997;336(13):964.
- Bradei M, Tayeb Abad M, . Hydroxyurea can eliminate transfusion requirements in children with severe β-thalassemia. Blood. 2003;102:1529–1530.
- Saxon BR, Waye JS, Olivier NF. Increase in hemoglobin concentration during therapy with hydroxyurea in Cooley's anemia. Ann N Y Acad Sci. 1998;850:459–460.
- Erlandson ME, Brilliant R, Smith CH. Comparison of sixty-six patients with thalassemia major and thirteen patients with thalassemia intermedia: including evaluations of growth, development, maturation and prognosis. Ann N Y Acad Sci. 1964;119:727–735.
- Savona-Ventura C, Bonello F. Beta-thalassemia syndromes and pregnancy. Obstet Gynecol Surv. 1994;49(2):129–137.
- Pearson Ha. Thalassemia intermedia; genetic and biochemical considerations. Ann N Y Acad Sci. 1964;119:390–401.
- Tefferi A, Elliot MA, Kao PC, . Hydroxyurea-induced marked oscillation of platelet counts in patients with polycythemia vera. Blood. 2000;96:1582–1584.
- Bénédicte C, Neonate MG, Girot R, Aractingi S. Cutaneous adverse reactions to hydroxyurea in patients with sickle cell disease. Arch Dermatol. 2001;137:467–470.
- Zargari O, Kimyai-Asadi A, Jafroodi M. Cutaneous adverse reactions to hydroxyurea in patients with intermedia thalassemia. Pediatr Dermatol. 2004;21:633–635.
- De Montalembert M, Begue P, Bernaudin F, . Preliminary report of a toxicity study of hydroxyurea in sickle cell disease. Arch Dis Child. 1999;81:437–439.
- Najean Y, Rain JD, for the French Polycythemia Study Group. Treatment of polycythemia vera: the use of hydroxyurea and pipobroman in 292 patients under the age of 65 years. Blood. 1997;90:3370–3377.
- Tothova E, Nebesnakova E, Kafkova A, . Leukemic transformation of polycythemia vera after treatment with hydroxyurea and chromosome 17 abnormalities. Vnitr Lek. 1999;45:487–489.
- Sterkers Y, Preudhomme C, Lai JL, . Acute myeloid leukemia and myelodysplastic syndromes following essential treated with hydroxyurea: high proportion of cases with 17p deletions. Blood. 1998;91:616–622.
- Finazzi G, Ruggeri M, Rodeghiero F, Barbui T. Second malignancies in patients with essential thrombocythemia treated with busulphan and hydroxyurea: long-term follow-up of a randomized clinical trial. Br J Haematol. 2000;110:577–583.